Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by State Street Corp

State Street Corp decreased its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 39.5% during the third quarter, according to its most recent filing with the SEC. The firm owned 3,192,436 shares of the biotechnology company's stock after selling 2,088,430 shares during the period. State Street Corp owned 2.10% of Heron Therapeutics worth $6,353,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in HRTX. Bank of New York Mellon Corp boosted its position in Heron Therapeutics by 33.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 449,212 shares of the biotechnology company's stock valued at $1,572,000 after acquiring an additional 113,655 shares in the last quarter. HB Wealth Management LLC bought a new stake in Heron Therapeutics during the second quarter valued at about $35,000. Panagora Asset Management Inc. grew its stake in Heron Therapeutics by 49.8% in the second quarter. Panagora Asset Management Inc. now owns 562,228 shares of the biotechnology company's stock valued at $1,968,000 after purchasing an additional 186,802 shares during the last quarter. nVerses Capital LLC bought a new position in Heron Therapeutics in the second quarter worth about $27,000. Finally, Rhumbline Advisers lifted its position in shares of Heron Therapeutics by 31.5% during the second quarter. Rhumbline Advisers now owns 184,472 shares of the biotechnology company's stock valued at $646,000 after buying an additional 44,230 shares during the last quarter. Hedge funds and other institutional investors own 80.01% of the company's stock.

Heron Therapeutics Trading Down 3.1 %

Shares of HRTX stock traded down $0.05 during trading hours on Friday, reaching $1.55. 1,805,938 shares of the company's stock were exchanged, compared to its average volume of 2,691,781. Heron Therapeutics, Inc. has a 1 year low of $1.04 and a 1 year high of $3.93. The stock has a market cap of $235.75 million, a PE ratio of -8.61 and a beta of 1.67. The stock's fifty day moving average price is $1.53 and its two-hundred day moving average price is $2.13.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.03). The company had revenue of $32.81 million for the quarter, compared to analyst estimates of $36.40 million. During the same quarter in the previous year, the company posted ($0.17) EPS. On average, equities analysts expect that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on HRTX shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research report on Wednesday, December 4th. StockNews.com lowered shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, December 19th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.